In a victory for Robert F. Kennedy Jr.’s “MAHA” agenda, panelists narrowly recommended broader use of four peptides despite a ...
The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results